Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label, Uncontrolled Study to Evaluate the Efficacy and Safety of ONO-4538 in Patients With Richter's Transformation
Investigate the efficacy and safety of ONO-4538 in patients with Richter's transformation
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Aichi Cancer Center
Nagoya, Aichi-ken, Japan
Kyusyu University Hospital
Fukuoka, Fukuoka, Japan
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
Hiroshima, Hiroshima, Japan
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
Kyoto University Hospital
Kyoto, Kyoto, Japan
Tohoku University Hospital
Sendai, Miyagi, Japan
Niigata University Medical & Dental Hospital
Niigata, Niigata, Japan
Kindai University Hospital
Ōsaka-sayama, Osaka, Japan
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Bunkyō-Ku, Tokyo, Japan
National Cancer Center Hospital
Chuo Ku, Tokyo, Japan
Start Date
November 19, 2025
Primary Completion Date
July 31, 2029
Completion Date
July 31, 2030
Last Updated
February 13, 2026
14
ESTIMATED participants
ONO-4538
DRUG
North America Clinical Trial Support Desk
CONTACT
+18665877745(Toll-Free)clinical_trial@ono-pharma.comLead Sponsor
Ono Pharmaceutical Co. Ltd
NCT03162536
NCT02378038
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions